Analyst Expectations for Coherus BioSciences's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Coherus BioSciences (NASDAQ:CHRS) stock, with 3 being bullish, 1 somewhat bullish, and none bearish. The average 12-month price target for the stock is $16.75, an increase of 4.69% from the previous average of $16.00.
October 23, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are bullish on Coherus BioSciences, with an increased 12-month price target.
The bullish sentiment from analysts, coupled with an increased 12-month price target, indicates a positive outlook for Coherus BioSciences. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100